1.30Open1.30Pre Close0 Volume1 Open Interest2.50Strike Price0.00Turnover0.00%IV3.23%PremiumDec 20, 2024Expiry Date1.26Intrinsic Value100Multiplier19DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.01Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Immunic Stock Discussion
2 MINUTES AGO, 6:30 AM EDT
VIA PR NEWSWIRE
Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline For All Progressive Multiple Sclerosis Subtypes –
– Clinical Signal Shown for Vidofludimus Ca...
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients With Post Covid Syndrome
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
PR Newswire· 1 min ago
No comment yet